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Summary
Background. — Recently, the Occlutech Figulla ASD Occluder (FSO) has been introduced for
transcatheter closure of atrial septal defects. This device can be used for transcatheter closure
of small as well as large atrial septal defects.
Aims. — To evaluate the feasibility and short-term results of transcatheter closure of secundum
type atrial septal defects using the FSO device in adult patients.
Methods. — Seventy-four consecutive adult patients were referred for transcatheter closure
of secundum large atrial septal defects (‘‘stretched’’ diameter > 20mm and/or invasive pul-
monary/systemic ﬂow [Qp/Qs] ratio > 1.5) using the FSO device.
Results. — The FSO device was successfully implanted in 68 patients (mean± SD [range] age:
31.8± 12.3 [17—64] years; weight: 71.5± 18.4 [49—98] kg). All patients had right atrial and
ventricular volume overload with a mean Qp/Qs ratio of 2.5± 0.6 (range 1.5—3.8). Mean atrial
22.3± 4.8 (range 12—33)mm and the size of the implanted FSO wasseptal defect diameter was
24.1± 4.9 (range 12—36)mm. Two patients had trivial (jet width < 1mm in diameter) residual
shunts and one patient had a small (1—2mm) residual shunt. There were no moderate or severe
residual shunts. No device embolization or other serious complication occurred during either
the procedure or the follow-up.
Abbreviations: ASD, atrial septal defect; ASO, Amplatzer Septal Occluder; ECG, electrocardiogram; FSO, Occlutech Figulla ASD
Occluder; TCC, transcatheter closure; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.
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Conclusion. — The present study found that transcatheter closure of isolated secundum atrial
septal defects using the novel design of the FSO device was safe, effective, and had an excellent
outcome during the 6month follow-up period.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation. — Le dispositif d’occludeur ﬁgulla (FSO) de fermeture percutanée des CIA a été
introduit récemment pour la fermeture percutanée des CIA et constitue une alternative pour
ces procédures, tant pour ce qui concerne les CIA de petites tailles, que les CIA larges.
Objectif. — Nous avons évalué la faisabilité des résultats à court terme de la fermeture par
cathéter transcutané de CIA ostium secondum en utilisant le dispositif d’occludeur ﬁgulla (FSO)
chez des adultes.
Matériels et méthodes. — Soixante-huit patients ont été adressés consécutivement pour fer-
meture percutanée de CIA ostium secondum large (diamètre étiré > 20mm et/ou rapport
QP/QS > 1,5) en utilisant ce nouveau dispositif percutané. L’âge moyen était de 31,8 + 12,3 ans
(extrême 17—63) et le poids moyen était de 71,5 + 18,4 kg (extrêmes 49—98). Tous les patients
présentaient une surcharge volumique auriculaire et ventriculaire droite avec un rapport QP/QS
moyen à 2,5 + 0,6 (extrême 1,5—3,8).
Résultats. — Le dispositif nouveau testé FSO a été implanté avec succès lors de 68 des
74 procédures (92 %). Le diamètre moyen de la CIA était de 22,3± 4,8mm (extrêmes 12—33mm)
et la taille moyenne du dispositif FSO implanté était de 24,1± 4,9mm (extrêmes 12—36mm).
Aucun patient n’a présenté de shunt résiduel signiﬁcatif, deux avaient un shunt minime. Il n’y
a pas eu d’embolisation du dispositif percutané ou d’autres complications sévères tant lors de
la procédure que lors du suivi.
Conclusions. — Notre étude a montré que la fermeture percutanée de CIA ostium secondum isolé
utilisant un nouveau dispositif percutané (FSO) est sûr, efﬁcace et est associé à un excellent
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ackground
he most common intervention for structural heart diseases
cross age groups is TCC of ASDs, which was ﬁrst described
n 1976 by King et al. [1]. Since then, very advanced tech-
iques and devices for TCC have been developed, and TCC
as been used with increasing frequency as an alternative
o open-heart surgery. Today, the ASO (AGA Medical, Golden
alley, MN, USA) is the most widely used device worldwide
or TCC of ASDs. Recently, the FSO (Occlutech GmbH., Jena,
ermany) was introduced for TCC of secundum ASDs. This
lternative device can be used for TCC of small as well as
arge ASDs. Construction and implantation procedures are
imilar to those of ASO. However, there are several major
dvantages of this novel device, including increased ﬂex-
bility, minimized implanted material, and the absence of
he left atrial clamp, which reduces trauma and clot forma-
ion risks on the left atrial disc [2] (Figs. 1—3). To the best
f our knowledge, there are very few data regarding TCC
f secundum ASDs using FSO devices in adults [2,3]. Here
e present early clinical experience and short-term results
rom our centre on TCC of secundum type ASDs using FSO
evices in 68 adult patients.
aterials and methodsatient population
etween September 2007 and January 2010, 74 consecu-
ive adult patients were referred for TCC of secundum large
S
T
Huivi (six mois).
s droits réservés.
SDs (‘‘stretched’’ diameter > 20mm and/or invasive pul-
onary/systemic ﬂow [Qp/Qs] ratio > 1.5) for placement of
he FSO device. Patients were recruited from Inonu Univer-
ity Cardiology Department, and written informed consent
as obtained from all participating patients. All patients
nderwent a physical examination, standard 12-lead ECG,
hest X-ray, TTE, and TOE. A complete blood count and sev-
ral additional tests were performed to identify patients
ith coagulation disorders.
xclusion criteria
atients were excluded if their secundum ASDs were:
ccompanied with other complex congenital cardiac mal-
ormations; had a defect stretched diameter > 35mm or an
nsufﬁcient septal tissue rim< 4mm from either atrioven-
ricular valve, the coronary sinus, or the right pulmonary
eins; multiple defects that could not be adequately cov-
red by the device; angiographically conﬁrmed acquired
oronary artery disease; or severe mitral and/or tricus-
id regurgitation. Patients diagnosed as having a bleeding
isorder; untreated ulcer; any contraindication to aspirin;
on-reactive elevated pulmonary vascular resistance; small
SDs with a Qp/Qs ratio < 1.5; or no signs of right ventricular
ilatation were also excluded [4].election of patients suitable for TCC
TE and TOE examinations were performed using an ATL
DI 5000 echocardiography machine (Bothell, WA, USA) and
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uFigure 1. The Occlutech Figulla device. Note the absence of the
a 5.0MHz biplane transoesophageal probe in all patients.
All echocardiographic measurements were obtained in three
different frames recorded at the same phase of the cardiac
cycle. TTE and TOE have been described in detail previ-
ously [5]. TCC of ASDs was performed under TOE monitoring
using the FSO. Although the balloon sizing method has been
accepted as the gold standard for the selection of device
size, it is not necessary in all ASD patients [6,7]. In this study,
Figure 2. Angiographic view of the Occlutech Figulla device after
release. Note the absence of the microscrew hub at the left atrial
disc.
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Ooscrew hub at the left atrial disc.
he stretched balloon diameter was measured under ﬂuo-
oscopy when the balloon occluded the defect completely.
alloon sizing was used in 22/74 patients with ASDs (29.7%),
sually in patients with a ﬂoppy septum. Before the proce-
ure, intravenous heparin (100 IU/kg) was administered to
eep the activated clotting time > 200 s. Also, 100mg aspirin
nd 75mg clopidogrel were given 1 day before the proce-
ure. The FSO implantation procedure is analogous to the
echnique used for ASO implantation. The TCC of ASDs tech-
ique has been described previously [5,8].
SO device
he FSO device is constructed from 0.082—0.186mm nitinol
ires that are tightly woven into two ﬂat round discs with a
mm-long connecting waist. The size of the device is deter-
ined by the diameter of the waist, and is available in the
izes shown in Table 1, which also shows the correspond-
ng sizes of the left and right atrial discs. The prosthesis
s ﬁlled with a polyester patch (thickness 30—45m) to
igure 3. Transoesophageal echocardiographic view of the
cclutech Figulla device after release.
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Table 1 Dimensions of the Occlutech Figulla device and delivery sheath for atrial septal defect size.
Waist diameter (mm) Left atrial disc (mm) Right atrial disc (mm) Delivery sheath (Fr) ASD size (mm)
6 18 14 7 D≤ 6
7.5 18 14 7 6 <D≤ 7.5
9 21 17 7 7.5 <D≤ 9
10.5 21 17 7 7 <D≤ 10.5
12 26 22 10 10.5 <D≤ 12
15 29 25 10 12.5 <D≤ 15
18 32 28 12 15 <D≤ 18
21 35 31 12 18 <D≤ 21
24 39 35 12 21 <D≤ 24
27 42 38 14 24 <D≤ 27
30 45 41 14 30 <D≤ 27
33 48 43 14 30 <D≤ 33
36 52 46 14 33 <D≤ 36
39 54 49 14 36 <D≤ 39
e
h
t
a
F
I
e
o
A
s
r
(
(
b
e
i
u
w
o
l
t
a
a
a
y
e
p
c
c
d
f
l
S
S
d
C
i
T
i
c
R
T
7
c
s
t
l
the balloon sizing method; and in the other three, TOE
demonstrated a septal tissue rim< 4mm from the atrioven-
tricular valves. Before the TCC of ASD, one patient had
atrial ﬁbrillation, and oral anticoagulation therapy was ini-
tiated after the procedure for this patient. Two patients had
Table 2 Patient demographics and procedure
characteristics.
All patients
(n = 68)
Females 41 (60.3)
Age (years) 31.8± 12.3 (17—64)
Weight (kg) 71.5± 18.4 (49—98)
Defect diameter (mm) 22.3± 4.8 (12—33)
Device diameter (mm) 24.1± 4.9 (12—36)
Device/defect ratio 1.1± 0.05
Qp/Qs ratio 2.5± 0.6 (1.5—3.8)
Fluoroscopy time (min) 18.7± 5.6
Procedure time (min) 54.8± 15.740 55 50
ASD: atrial septal defect; D: diameter.
nhance thrombogenicity. There is only one stainless steel
ub (microscrew) at the right atrial disc for cable connec-
ion (Figs. 1—3). The size of the required delivery sheaths
re shown in Table 1.
ollow-up
mmediately after the release of the FSO, a precise TOE
xamination was performed to evaluate the shape of the
ccluder and search for thrombus formation on the device.
detailed colour Doppler interrogation of the interatrial
eptum was performed, mainly to detect and quantify any
esidual shunts. Residual shunts were graded as: trivial
jet width < 1mm in diameter), small (1—2mm), moderate
> 2 but < 4mm), or severe (≥ 4mm) [9]. The relationship
etween the occluder and the atrioventricular valves was
valuated. Drainage of the vena cava superior/vena cava
nferior, right pulmonary veins and coronary sinus were eval-
ated for obstruction.
At 24-hour follow-up, ECG, chest radiograph, and TTE
ere performed. The presence of a thrombus on both discs
f the FSO was searched for using TTE. Residual shunts were
ooked for and quantiﬁed using colour Doppler. The rela-
ionship of both atrioventricular valves towards the FSO was
ssessed. Drainage of the caval veins, right pulmonary veins
nd coronary sinus were evaluated for obstruction. There-
fter, ECG and TTE were scheduled at 1month, 6 months, 1
ear and then annually after the procedure. The same TTE
xamination protocol was used throughout the follow-up
eriod as was performed 24 hours after the procedure.
The patient was discharged with the following medi-
al recommendations/advice: dual platelet inhibition was
ontinued with 100mg aspirin for 6months and 75mg clopi-
ogrel for 1—3months; and standard antibiotic prophylaxis
or endocarditis (dental, gastroenterological, and gynaeco-
ogical procedures) for 180 days.tatistical analysis
tatistical analysis was performed using SPSS for Win-
ows version 17.0 software (SPSS Inc, Chicago, IL, USA).14 39 <D≤ 40
ontinuous variables are expressed as mean± SD. Categor-
cal variables are expressed as numbers and percentages.
he paired t-test was used for comparison of variables stud-
ed at baseline and 6 months after TCC of ASD. P < 0.05 was
onsidered signiﬁcant.
esults
he FSO device was successfully implanted during 68 of
4 procedures (91.9%). Patient demographics of those suc-
essfully implanted are shown in Table 2. The remaining
ix patients were excluded prior to attempted implan-
ation as per the protocol: in three, the ASD was too
arge (> 35mm) after TOE and catheter assessment withHospital stay 1 day for all patients 1.1± 0.1
Qp/Qs: pulmonary/systemic ﬂow. Data expressed as mean± SD
with or without (range) or n (%).
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Table 3 Echocardiographic variables in patients with ASD before and 6 months after TCC.
Before TCC (n = 68) 6 months after TCC (n = 68) P
LVEF (%) 62.6 ± 5.6 65.5 ± 4.2 < 0.0001
LVEDD (mm) 43.5 ± 3.6 45.4 ± 3.2 < 0.0001
LVESD (mm) 26.1 ± 3.4 26.2 ± 3.2 0.581
Septal thickness (mm) 9.2 ± 1.0 9.2 ± 0.8 0.658
PW thickness (mm) 9.2 ± 0.7 9.2 ± 0.9 1.0
RVEDD (mm) 44.8 ± 5.9 39.2 ± 5.4 < 0.0001
RVOT (mm) 39.6 ± 5.2 36.1 ± 5.1 < 0.0001
Left atrial diameter (mm) 39.2 ± 3.8 36.9 ± 3.7 < 0.0001
Right atrial diameter (mm) 52.4 ± 10.5 45.4 ± 9.6 < 0.0001
Systolic pulmonary artery pressure (mmHg) 39.3 ± 6.9 32.1 ± 4.4 < 0.0001
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end-systolic diameter; RVEDD: right ventricular end-diastolic diam
transcatheter closure. Data expressed as mean± SD.
atrial arrhythmias: supraventricular tachycardia resolved
after using antiarrhythmic therapy; and frequent atrial
extrasystoles disappeared spontaneously 24 hours after the
procedure. The mean ASD diameter was 22.3mm; and the
mean size of the implanted FSO was 24.1mm (Table 2).
Immediately after the procedure, as documented by
colour Doppler echocardiography (TOE in all patients), two
patients had trivial residual shunts, and one had a small
residual shunt. There were no moderate or severe residual
shunts. At 6month follow-up by TTE, one patient had a small
residual shunt.
There were no serious complications (e.g. aortic regur-
gitation; narrowing of coronary sinus, pulmonary vein,
inferior or superior vena cava; obstruction of intracardiac
structures; attacks of infective endocarditis; thromboem-
bolism; cardiac perforation; aorta-to-right-atrial ﬁstulae;
pericardial effusion; device wire fracture; deformation of
implanted device; or whole-device embolization) both dur-
ing the procedure and 6 months after TCC of ASDs. The mitral
and tricuspid valves were not encroached upon by the FSO
device in any of the patients enrolled in the study.
All echocardiographic ﬁndings of the ASD patients before
and 6 months after TCC are presented in Table 3. Left
ventricular ejection fraction (LVEF) and left ventricular
end-diastolic diameter (LVEDD) had increased signiﬁcantly
6 months after TCC (Table 3), but there were no sig-
niﬁcant changes in left ventricular end-systolic diameter
(LVESD), interventricular septal thickness, or left ventricu-
lar posterior wall (PW) thickness (Table 3). Right ventricular
end-diastolic diameter (RVEDD), right ventricular outﬂow
tract (RVOT), and left and right atrial diameters had all
decreased signiﬁcantly 6 months after TCC (Table 3). Systolic
pulmonary artery pressure had also decreased signiﬁ-
cantly 6 months after TCC (39.3± 6.9 to 32.1± 4.4mmHg;
P < 0.0001).
DiscussionSince the introduction of the ASD Occluder devices [1],
many such devices have been developed for TCC with vari-
able degrees of success [1,10—16]. In the present study, we
used a new ASD occluder, the FSO, in patients with isolated
m
d
b
[r; LVEF: left ventricular ejection fraction; LVESD: left ventricular
; RVOT: right ventricular outﬂow tract; PW: posterior wall; TCC:
ecundum type ASD. To date, there is a paucity of short-term
ata and experience regarding TCC of secundum ASDs using
he FSO devices in adults [2,3], and there are no long-term
ata. In the present study, complete occlusion was achieved
n 68/74 patients (91.9%), with no mortality or signiﬁcant
omplications during a short-term follow-up period (up to
months). Therefore, our study demonstrates and conﬁrms
he safety and the excellent outcome of TCC of ASDs using
he novel design of the FSO device.
The construction of the FSO is similar to that of the ASO.
owever, there are some important structural innovations
n favour of the novel FSO. The ASO device is made up of a
itinol wire tube that is clamped in two stainless steel hubs,
ne on each side of the disc. In contrast, the FSO device is
ndividually braided, avoiding a distal clamp (Figs. 1—3). The
otential beneﬁts of this are a decreased risk of thrombus
ormation on the left atrial disc and increased the ﬂexibility
f the device [2]. Sigler and Jux have demonstrated that
rotruding metal parts, like the microscrew of the ASO and
he spring arms of the CardioSEAL/STARﬂex devices, were
he last parts of the septal occluders to endothelialize [17].
hus, the surfaces of these parts carry the risk of device-
elated thrombus formation at an early stage.
Previous studies have demonstrated that the incidence
f thrombus formation in TTC of ASD, particularly with the
SO device, was lower the than other devices, such as
ardioSEAL, StarFLEX, and PFO-Star [18—20]. Similarly, in
he present study, we detected no thrombus formation or
ystemic thromboembolism in the patients during the pro-
edure or the follow-up. However, long-term prospective
tudies are needed to determine whether the reduction of
aterial in the left atrial disc can reduce the thromboem-
olic complications, following TCS of ASD with the FSO.
Even though the implantation technique of the FSO is sim-
lar to that of the ASO, the increased ﬂexibility and reduced
mount of material implanted in the left atrial disc make the
SO devices safer and more comfortable during implantation
han other devices [21]. This device is very easy to handle,
nd can be recaptured after deployment of both discs, thus
aking it quite easy to reposition [3,22]. Additionally, the
elivery system allows improvements in product handling
ecause of its ﬁnal positioning without any adverse tension
23].
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Major disadvantages of the FSO device are the require-
ents of a two Fr [7—14 in Table 1] size sheath and
larger delivery system than the ASO device. It is well
nown that complications of femoral vein access may be
lightly increased with larger venous sheaths [24]. How-
ver, we do not think that this is too concerning, as the
ccess is from the venous system in adults, and there
ere no complications (e.g. right iliac vein dissection, groin
aematoma or retroperitoneal haemorrhage [18]) during
CC of ASD using the FSO in our study. However, addi-
ional care should be taken when using the FSO device
n childhood. Furthermore, this device should be carefully
valuated in further studies.
After the ASO device implantation, new-onset arrhyth-
ias are the most common early complication [25], but
igniﬁcant arrhythmias (e.g. persistent or transient com-
lete atrioventricular block) have only rarely been reported
9,11]. In this study, we noted that two patients had
trial arrhythmias: supraventricular tachycardia resolved
fter using antiarrhythmic therapy and frequent atrial
xtrasystoles disappeared spontaneously 24 hours after the
rocedure. Also, there was no signiﬁcant or persistent atrial
r ventricular arrhythmia in our patients during the follow-
p after the FSO device implantation.
onclusions
he present study shows that TCC of isolated secundum
SD using the novel design of the FSO device is safe
nd effective. We had a high success rate, and immedi-
te and short-term results were encouraging. However, in
he present study, we only had a short follow-up time (6
onths). As long-term follow-up is currently not available
or this device, these initial short-term ﬁndings should be
valuated in further long-term prospective studies including
arger numbers of patients.
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